Skip to content
Screener

Exelixis EXEL Operating Cash Flow

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$10.69B+246%
Pfizer logo
PfizerPFE
$2.62B+12.0%
Kura Oncology logo
Kura OncologyKURA
-$85.85M-19.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$44.36M-6.4%
Immunome logo
ImmunomeIMNM
-$58.64M-10.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$119M+10.5%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Prepaid expenses and other assets99,156(84,386)
Accrued collaboration liabilities(5,262)641
Accounts payable and other liabilities(12,866)(55,007)
Net cash provided by operating activities559,586260,430
Cash flows from investing activities:
Purchases of marketable securities(342,683)(288,186)
Proceeds from maturities and sales of marketable securities394,393612,021
Purchases of property, equipment and other, net(8,325)(5,790)

Item 1. Financial Statements.

FAQ

What is Exelixis's operating cash flow?
Exelixis (EXEL) reported operating cash flow of $307.74M in Q2 2026.
How has Exelixis's operating cash flow changed year-over-year?
Exelixis's operating cash flow increased by 528.1% year-over-year, from $48.99M to $307.74M.
What is the long-term trend for Exelixis's operating cash flow?
Over 4 years (2021 to 2025), Exelixis's operating cash flow has grown at a 21.9% compound annual growth rate (CAGR), from $400.8M to $884.27M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Exelixis's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude